Close Menu

Keygene

The company holds and licenses a variety of IP related to high-throughput genotyping, sample pooling, and methods involved in oligonucleotide ligation-based assays.

The companies will use their respective technologies to optimize the cannabinoid profiles and other traits of different cannabis varieties.

The disagreement began when NuGen filed a lawsuit seeking a ruling of non-infringement of two of KeyGene's US patents related to next-generation sequencing.

KeyGene and its parent firm, KeyGene NV, were named as defendants in a NuGen Technologies suit seeking to invalidate two US patents.

The patent claims strategies for identifying optimal breeding combinations of crop plants or cattle within a breeding population.

The technology allows for genome-wide SNP discovery and genotyping in large populations of organisms in a single experiment.

The company also extended its existing licensing agreement with Genalice, signed in 2013, to improve plant DNA analysis.

The assembly of the agricultural pest Rhizoctonia solani genome was more contiguous and larger than previous short-read assemblies.

The two companies will use KeyGene's technology for the genetic analysis of field and vegetable crops.

The deal allows Floragenex to extend its SBG service offerings to include double digest RAD-Seq in non-commercial and academic research across all species.

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.